$SGMO News

Sangamo Therapeutics, Inc. (SGMO) Presents at 29th ASGCT Annual Meeting 2026 - Slideshow

Sangamo Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Sangamo Therapeutics Inc (NASDAQ:SGMO) Misses Q1 2026 Estimates, Stock Plunges 15.6%

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

Full Transcript: Sangamo Therapeutics Q1 2026 Earnings Call

Sangamo Therapeutics Q1 EPS $(0.08) Misses $0.01 Estimate, Sales $1.442M Miss $33.725M Estimate

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

Sangamo Therapeutics To Switch Trading From Nasdaq To OTCQB Venture Market, Effective May 5

Sangamo Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Sangamo Therapeutics, Inc. Q4 2025 Earnings Call Summary

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ...

Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript

Sangamo Therapeutics Q4 EPS $(0.11) Misses $(0.06) Estimate, Sales $14.200M Miss $16.475M Estimate

Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates

Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call